{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:17:05Z","timestamp":1788617825647,"version":"build-2803163510"},"reference-count":16,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2022]]},"DOI":"10.3960\/jslrt.22001","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T22:09:28Z","timestamp":1655849368000},"page":"158-163","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative evaluation of treatment response to lenalidomide by applying fluorescence &lt;i&gt;in situ&lt;\/i&gt; hybridization for peripheral blood granulocytes in a patient with 5q\u2013 syndrome"],"prefix":"10.3960","volume":"62","author":[{"given":"Hirotaka","family":"Sakai","sequence":"first","affiliation":[{"name":"Division of Hematology, Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan,"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan,"},{"name":"Center for Genetic and Chromosomal Analysis, SRL, Inc., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality (\u201c5q\u2013 syndrome\u201d). In: Jaffe ES, Harris NL, Stein H (eds): Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer. 2001; pp. 73.","DOI":"10.1182\/ashimagebank-2001-100197"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Van den Berghe H, Cassiman JJ, David G <i>et al.<\/i> Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974; 251: 437-438.","DOI":"10.1038\/251437a0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogenet. 1985; 17: 189-255.","DOI":"10.1016\/0165-4608(85)90016-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Boultwood J, Pellagatti A, McKenzie ANJ, Wainscoat JS. Advances in the 5q- syndrome. Blood. 2010; 116: 5803-5811.","DOI":"10.1182\/blood-2010-04-273771"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 List A, Kurtin S, Roe DJ <i>et al.<\/i> Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-557.","DOI":"10.1056\/NEJMoa041668"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 List A, Dewald G, Bennett J <i>et al.<\/i> Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.","DOI":"10.1056\/NEJMoa061292"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Harada H, Watanabe M, Suzuki K <i>et al.<\/i> Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol. 2009; 90: 353-360.","DOI":"10.1007\/s12185-009-0400-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Pellagatti A, Boultwood J. Recent advances in the 5q- Syndrome. Mediterr J Hematol Infect Dis. 2015; 7: e2015037.","DOI":"10.4084\/mjhid.2015.037"},{"key":"9","unstructured":"9 Hasserjian RP, Le Beau MM, List AF, et al. Myelodysplastic syndrome associated with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, et al. (eds): WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, International Agency for Research on Cancer. 2017; pp. 115-116."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Greenberg PL, Tuechler H, Schanz J <i>et al.<\/i> Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120: 2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Sato K, Sakai H, Saiki Y <i>et al.<\/i> Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia. Int J Hematol. 2018; 108: 274-281.","DOI":"10.1007\/s12185-018-2472-9"},{"key":"12","unstructured":"12 Saiki Y, Sakai H, Uchida A <i>et al.<\/i> [Leukemic cell kinetics of APL with a novel complex variant t (12;17;15)(p13;q21;q22)]. Rinsho Ketsueki. 2020; 61: 103-109."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Anderson K, Arvidsson I, Jacobsson B, Hast R. Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies. Cancer Genet Cytogenet. 2002; 136: 101-107.","DOI":"10.1016\/S0165-4608(02)00515-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Jaju RJ, Jones M, Boultwood J <i>et al.<\/i> Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome. Genes Chromosomes Cancer. 2000; 29: 276-280.","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1035>3.0.CO;2-L"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nilsson L, \u00c5strand-Grundstr\u00f6m I, Arvidsson I <i>et al.<\/i> Isolation and characterization of hematopoietic progenitor\/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000; 96: 2012-2021.","DOI":"10.1182\/blood.V96.6.2012.h8002012a_2012_2021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Takahashi N, Miura I, Kobayashi Y <i>et al.<\/i> Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int J Hematol. 2005; 81: 235-241.","DOI":"10.1532\/IJH97.04095"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:43:06Z","timestamp":1715233386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/62\/3\/62_22001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.22001","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22001"}}